Rossari Biotech Ltd

- Ongoing capacity expansion projects across Rossari Biotech, Unitop Chemicals, and Tristar Intermediates progressing in phases. - These expansions aim to eliminate capacity constraints, enhance supply chain agility, and strengthen positioning in high-growth sectors. - Commissioning of new capacities expected in upcoming quarters, with full operation and optimal utilization anticipated by FY27, delivering 3x-4x asset turns. - An overseas formulation facility is being set up in Southeast Asia with an initial CAPEX of around Rs. 15-20 crore to enhance international presence and customer engagement. - Investments are funded through a mix of internal accruals and debt. - CAPEX work impacted production temporarily due to safety protocols but is on track. - Full benefit of expanded Ethylene Oxide (EO) capacity expected mostly from September-October 2026, with capacity ramp-up continuing over 3-4 years. - Focus on phased commissioning and strategic investments to drive scalable and profitable growth from FY27 onwards.

- Rossari Biotech expects mid-double-digit revenue growth of around 14%-15% annually over the next 2 years. - Export sales are anticipated to make up approximately 27%-28% of overall turnover on an annualized basis. - The Institutional Cleaning and Consumer Business vertical is expected to grow healthily on an annual basis, especially in subsequent quarters after Q1. - The B2B business is projected to grow at a faster pace over the next 2-3 years once EO availability improves and new capacities attain optimal utilization. - Volume growth in exports has been 11% YoY despite temporary disruptions, indicating robust demand. - Capacity expansion projects are underway and expected to deliver 3x-4x asset turnover and margin expansion from FY27 onwards. - The overseas formulation facility in Southeast Asia will support future international growth and stronger customer engagement in the region.

- Rossari Biotech expects mid-double-digit (14%-15%) growth in both revenue and EBITDA over the next 2 years (Page 8). - EBITDA margin excluding losses from the institutional and consumer business was around 16%; newer verticals are expected to turn margin-accretive by FY27 (Page 4, 11). - The Institutional and B2C business losses are expected to reduce substantially this year, with potential to break even at EBITDA level by FY26 or latest FY27 (Page 10, 11). - Capacity expansions will drive 3x-4x asset turns at optimal utilization, supporting margin expansion and scalable profitable growth, especially from FY27 onwards (Pages 3, 4). - Export growth normalized with expected improvement from Q2 onwards, aiding overall revenue growth (Pages 7, 9). - EO supply constraints easing with anticipated full capacity by FY28, supporting production ramp-up and growth (Pages 6, 9). Overall, the company is building a strong foundation aiming for scalable, profitable growth post FY26.

- The company did not provide specific figures regarding the current or expected orderbook/pending orders during the call. - It was mentioned that some institutional orders are phased and expected to be fulfilled over the next couple of quarters, indicating a pipeline of pending orders. - The Institutional Consumer business experienced a softer Q1 but is expected to show healthy growth on an annual basis. - Q2 and Q3 are anticipated to be stronger quarters for fulfilling institutional orders. - Export orders missed in Q1 due to production downtime are expected to be fulfilled in Q2. - Overall, the company is optimistic about good growth and order execution in the near term, viewing short-term softness as exceptional rather than indicative of longer-term trends.

- The company is funding its ongoing and upcoming CAPEX projects through a mix of internal accruals and debt. - No explicit mention of new equity fundraising in the call transcript. - The balance sheet remains healthy with strong liquidity and conservative leverage, providing flexibility for growth initiatives. - Future CAPEX plans, including the overseas formulation facility, are expected to be modest initially (around Rs. 15-20 crore) and may expand depending on market acceptance. - Management's focus is on disciplined execution of growth initiatives funded primarily through internal resources and manageable debt levels rather than new large-scale fundraising at this stage.